Abivax (ABVX) Competitors $84.01 -1.95 (-2.27%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$81.64 -2.37 (-2.82%) As of 04:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABVX vs. TEVA, SMMT, GMAB, ASND, VTRS, RDY, QGEN, BBIO, MRNA, and VRNAShould you be buying Abivax stock or one of its competitors? The main competitors of Abivax include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. Abivax vs. Its Competitors Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories QIAGEN BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Teva Pharmaceutical Industries (NYSE:TEVA) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk. Which has better valuation & earnings, TEVA or ABVX? Abivax has lower revenue, but higher earnings than Teva Pharmaceutical Industries. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.54B1.38-$1.64B-$0.16-124.75AbivaxN/AN/A-$190.71MN/AN/A Which has more risk and volatility, TEVA or ABVX? Teva Pharmaceutical Industries has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, Abivax has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Do analysts rate TEVA or ABVX? Teva Pharmaceutical Industries currently has a consensus price target of $24.71, suggesting a potential upside of 23.82%. Abivax has a consensus price target of $99.43, suggesting a potential upside of 18.35%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, equities research analysts clearly believe Teva Pharmaceutical Industries is more favorable than Abivax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Abivax 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Does the media favor TEVA or ABVX? In the previous week, Abivax had 14 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 25 mentions for Abivax and 11 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 1.21 beat Abivax's score of 0.65 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 5 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of TEVA or ABVX? 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is TEVA or ABVX more profitable? Abivax has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -0.95%. Teva Pharmaceutical Industries' return on equity of 46.10% beat Abivax's return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-0.95% 46.10% 7.18% Abivax N/A N/A N/A SummaryTeva Pharmaceutical Industries beats Abivax on 10 of the 14 factors compared between the two stocks. Get Abivax News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABVX vs. The Competition Export to ExcelMetricAbivaxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.35B$3.15B$5.78B$10.18BDividend YieldN/A2.32%5.73%4.60%P/E RatioN/A21.5775.5726.02Price / SalesN/A254.90461.9291.11Price / CashN/A44.4425.8129.91Price / Book121.759.6112.526.25Net Income-$190.71M-$53.29M$3.29B$270.76M7 Day Performance-6.66%0.57%0.78%2.54%1 Month Performance19.26%4.56%4.56%5.73%1 Year Performance616.81%10.44%66.82%25.85% Abivax Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABVXAbivax2.5649 of 5 stars$84.01-2.3%$99.43+18.4%+616.8%$6.35BN/A0.0061News CoveragePositive NewsEarnings ReportAnalyst ForecastShort Interest ↑TEVATeva Pharmaceutical Industries2.6589 of 5 stars$19.30+1.8%$24.71+28.1%+8.4%$21.73B$16.54B-120.6136,830SMMTSummit Therapeutics3.0725 of 5 stars$19.44-25.2%$33.79+73.8%-40.7%$19.30BN/A-19.25110Gap UpHigh Trading VolumeGMABGenmab A/S3.9502 of 5 stars$27.54flat$37.60+36.5%+3.4%$17.67B$3.12B13.842,682Positive NewsASNDAscendis Pharma A/S3.1642 of 5 stars$205.22-0.3%$244.36+19.1%+64.0%$12.60B$393.54M-39.771,017Positive NewsVTRSViatris1.4393 of 5 stars$10.48-0.2%$10.40-0.8%-14.6%$12.24B$14.74B-3.6132,000RDYDr. Reddy's Laboratories2.2636 of 5 stars$14.27-0.5%$16.95+18.8%-8.9%$11.97B$3.81B21.6127,811Positive NewsQGENQIAGEN4.4736 of 5 stars$47.62+0.1%$49.69+4.4%+0.5%$10.57B$1.98B28.135,765BBIOBridgeBio Pharma4.4426 of 5 stars$54.29+1.7%$63.35+16.7%+95.6%$10.20B$221.90M-13.27400Analyst ForecastMRNAModerna4.4699 of 5 stars$24.83-1.2%$42.88+72.7%-65.6%$9.78B$3.24B-3.305,800VRNAVerona Pharma PLC American Depositary Share2.31 of 5 stars$106.300.0%$109.00+2.5%+257.4%$9.20B$42.28M-107.3730Positive News Related Companies and Tools Related Companies TEVA Competitors SMMT Competitors GMAB Competitors ASND Competitors VTRS Competitors RDY Competitors QGEN Competitors BBIO Competitors MRNA Competitors VRNA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABVX) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abivax SA Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Abivax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABVX Stock Alerts